Quintiles has expanded its capabilities to include anatomic pathology services through its central lab in Beijing, China, in an effort to help Biopharmaceutical companies develop more effective cancer treatments. These services complement Assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

“Within China, we are providing the tools and infrastructure to investigate cancer and match patients with optimum treatments for their genetic makeup,” said Christopher Ung, vice president strategic business and operations, Oncology for Quintiles. “These capabilities enable Personalized medicine and enhance oncology research to bring medicines to market faster.”

Additionally, the Beijing anatomic pathology lab was accredited by the College of American Pathologists (CAP). This accreditation is issued following an on-site evaluation by a team of practicing lab professionals who examine records, quality control, staff qualifications, equipment, safety, and overall site management.